SENS Research Foundation works to develop, promote, and ensure widespread access to therapies that cure and prevent the diseases and disabilities of aging by comprehensively repairing the damage that builds up in our bodies over time. We are redefining the way the world researches and treats age-related ill health, while inspiring the next generation of biomedical scientists.

Discover the science behind our strategies to extend a healthy lifespan.

Training a new generation of scientists to tackle the roots of age-related disease.

Keep up to date on SRF’s latest news and activities.

The National Institute on Aging (NIA) division of the National Institutes of Health (NIH) has awarded a grant to advance research on Engineered Cyclodextrins targeting toxic oxidized cholesterol to eradicate atherosclerosis — the cause of most heart attacks and strokes.

Former SRF V.P. of Research and current Underdog Co-founder Matthew O’Connor, Ph.D. and current SRF V.P. of Research Alexandra Stolzing, Ph.D., are the Principal Investigators.

Underdog Pharmaceuticals’ research has combined computational and synthetic chemistry programs to custom-engineer cyclodextrins to capture, and remove from cells, oxidized cholesterol derivatives such as 7-ketocholesterol.

We are excited about how this collaboration will contribute to the advancement of our mission to develop, promote, and ensure widespread access to therapies that cure and prevent the diseases and disabilities of aging.

We are pleased to announce that the ApoptoSENS team led by Dr. Amit Sharma at the SRF Research Center has recently been granted a Catalyst award, courtesy of the Healthy Longevity Global Competition, to continue and expand their critical work on the interactions between senescent cells and natural killer (NK) cells.

Supported by the award, the ApoptoSENS team will now investigate whether the age-related loss of NK cell effectiveness in clearing senescent cells is reversible, and whether this may provide routes for therapeutic intervention. If successful, this work will clear a major hurdle to realizing NK cell-based treatments for senescent cell elimination.

Thanks to all of you who have been patiently waiting for SRF Education updates. We are currently undergoing some restructuring, and working to make our student internship and enrichment programs better than ever.

We are happy to announce that we have now opened applications for the 2022 Summer Scholars program. Please visit the program homepage for details, eligibility requirements, and to apply.

Applications will be accepted until noon PST on Tuesday February 1st, 2022.

A list of host laboratories will be posted as soon as we have it available.

Please note that the Postbaccalaureate Fellowship program is not currently expected to run in 2022-2023. We appreciate your continued patience during this transitionary period.

The News:

SRF’s researchers presenting our work at Indian biosciences conferences

Our VP of Research Dr. Alex Stolzing and Senescence Immunology Research Group Lead Dr. Amit Sharma will be presenting at conferences in India this week, including at the 35th Annual Conference of Aging Interventions, organized by the Society of Neurochemistry, India (SNCI), and the Darwin International Conference.

British Daily Mirror featured an interview with SENS Research Foundation’s Science Writer Michael Rae about the world’s richest men taking on the longevity challenge

As part of the widespread media coverage of the launch of Altos Labs and the rising tide of investment into rejuvenation biotechnology, a recent article in a British daily featured an interview with SENS Research Foundation’s Science Writer Michael Rae on Altos Labs, cellular reprogramming, and its place within the SENS platform of rejuvenation biotechnologies and the push toward a future of indefinite medical maintenance of healthy, youthful life.

Longevity Science Foundation’s $1 billion, 10 year distribution shows shift in attitudes since SRF inception

SRF is elated at the announcement in Longevity Technology of a fund that will distribute more than $1 billion over a ten year period specifically “to research, institutions and projects advancing healthy human longevity and extending the healthy human lifespan to more than 120 years.”

Few may remember the environment in which SRF began, in which interest in longevity research and significant extension of human life was far outside the mainstream. This financial commitment is another hard-fought victory in shifting attitudes towards fighting aging.

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2021 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can